stockportfolio.pro
Stocks / BMY vs MDT
BMY vs MDT
Bristol-Myers Squibb Company and Medtronic plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | Medtronic plc (MDT) | |
|---|---|---|
| Market cap | $115.3B | $105.3B |
| Revenue (latest FY) | $48.19B | $36.33B |
| Net income (latest FY) | $7.05B | $4.80B |
| Revenue growth (5y CAGR) | 2.5% | 3.8% |
| Net margin | 14.6% | 13.2% |
| Return on equity | 38.2% | — |
| P/E ratio | 15.8 | 22.0 |
| Dividend yield | 4.5% | 3.6% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open MDT — freeFrequently asked questions
Which is bigger, BMY or MDT?
Bristol-Myers Squibb Company is larger by market capitalization — $115.3B versus $105.3B.
Which grows faster, BMY or MDT?
Over the last five fiscal years, Medtronic plc grew revenue faster — 3.8%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.